Immucell financials
$9.94+0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M | $19.2M | $15.3M | $13.7M | $11.0M | $10.4M | $9.5M |
| Gross profit | $11.4M | $7.9M | $3.9M | $7.6M | $8.7M | $6.9M | $6.7M | $5.2M | $5.2M | $5.4M |
| Gross margin | 41.4% | 30.0% | 22.1% | 41.2% | 45.0% | 44.7% | 49.1% | 47.3% | 50.1% | 56.8% |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M | $257.4K | -$1.4M | -$953.9K | -$2.1M | -$242.8K | $890.2K |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M | -$78.3K | -$1.0M | -$1.3M | -$2.3M | -$168.1K | $508.4K |
| Net margin | −3.8% | −8.1% | −33.1% | −13.4% | −0.4% | −6.7% | −9.4% | −21.1% | −1.6% | 5.3% |
| Diluted EPS | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 | $-0.14 | $-0.19 | $-0.42 | $-0.03 | $0.12 |
| EBITDA | $4.4M | $1.0M | -$3.0M | $188.6K | $2.7M | $966.9K | $1.3M | -$625.9K | $661.6K | $1.7M |
| Operating cash flow | $2.5M | $357.9K | -$4.7M | -$1.5M | $954.2K | $1.3M | $233.5K | -$373.4K | $1.2M | -$222.3K |
| Free cash flow | $1.2M | -$107.8K | -$6.6M | -$5.5M | -$1.7M | -$2.8M | -$1.2M | -$2.4M | -$16.6M | -$4.3M |
| Diluted shares | 9.0M | 8.2M | 7.7M | 7.7M | 7.6M | 7.2M | 6.8M | 5.5M | 4.9M | 4.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.8M | $3.8M | $978.7K | $5.8M | $10.2M | $6.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $996.5K |
| Total debt | $9.1M | $10.5M | $12.0M | $10.2M | $9.1M | $9.5M |
| Total assets | $42.5M | $45.1M | $43.8M | $44.9M | $44.5M | $40.3M |
| Total liabilities | $15.5M | $17.6M | $18.8M | $14.5M | $11.9M | $12.1M |
| Shareholders' equity | $27.1M | $27.5M | $25.0M | $30.4M | $32.6M | $28.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology